SCHEMBL13718652

SCHEMBL13718652

CC(C)Cc1ccc(-c2ccccc2Cl)o1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.48
LMNA P02545 2/20 0.48
ALDH1A1 P00352 4/20 0.46
MAPK1 P28482 2/20 0.46
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
NPSR1 Q6W5P4 1/20 0.45
TP53 P04637 1/20 0.42
FTO Q9C0B1 1/20 0.41
ERCC5 P28715 1/20 0.41
FEN1 P39748 1/20 0.41
KDM4E B2RXH2 2/20 0.41
MCHR1 Q99705 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
SLC9A1 P19634 1/20 0.39
CASP3 P42574 1/20 0.39
RECQL P46063 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SENP7 Q9BQF6 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13749573 0.81 LMNA (0.51) MAPTLMNAALDH1A1MAPK1MEN1
SCHEMBL13719298 0.81 MAPT (0.45) MAPTLMNAALDH1A1MAPK1MEN1
SCHEMBL282040 0.77 ALDH1A1 (0.53) MAPTLMNAALDH1A1MAPK1MEN1
SCHEMBL12715362 0.77 CYP3A4 (0.56) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL6110304 0.77 LMNA (0.43) MAPTLMNAALDH1A1MAPK1MEN1
SCHEMBL13718749 0.76 SMN1; SMN2 (0.51) MAPTLMNAALDH1A1NPSR1KDM4E
SCHEMBL9970933 0.75 ALDH1A1 (0.50) MAPTLMNAALDH1A1MAPK1MEN1
SCHEMBL13541830 0.75 HRH1 (0.62) MAPTALDH1A1MEN1KMT2AKDM4E
SCHEMBL13718757 0.75 FTO (0.49) MEN1KMT2AFTOSMN1; SMN2
SCHEMBL12903065 0.74 FTO (0.54) MAPTLMNAALDH1A1MAPK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7579479-B2 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-25 US disclosed
US-7241780-B2 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method BRISTOLS-MYERS SQUIBB COMPANY (US) 2007-07-10 US disclosed
US-20070015797-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method CHENG PETER T 2007-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015797-A1 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method GPR119, LIPC, ACACA MAPT 4848/4885LMNA 320/4885ALDH1A1 1055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.